

# Effect of oral supplementation with micronized ferric pyrophosphate in pregnant women to prevent postpartum hemorrhage

Federica Di Napoli<sup>1</sup> , Luigi Vigilante<sup>2</sup> , Maria Giuseppina Trinchillo<sup>2</sup> , Gennaro Esposito<sup>2</sup> ,  
Maddalena Turco<sup>2</sup> , Elisabetta Gragnano<sup>1</sup> , Dario Colacurci<sup>1</sup> , Gabriele Saccone<sup>1</sup> 

1

2

## Abstract

**Objective:** The aim of this study was to evaluate the impact of oral supplementation with micronized ferric pyrophosphate in pregnant women to prevent postpartum hemorrhage

**Methods:** This was an observational retrospective study using data from clinical records of women with anemia who had visits at our private setting center. In this study, women who received oral supplementation with oral Sunactive Fe Pyrophosphate plus Vitamin C, Folate, and Vitamin B12 daily as prophylactic treatment for iron deficiency anemia were compared with women who did not. The intervention group received the supplementation starting from the diagnosis of anemia until the day of delivery. The control group received standard care, i.e. ferrous sulphate (daily 80 mg Fe+2), starting from the diagnosis of anemia until the day of delivery.

**Results:** PPH occurred in 11/250 women in the intervention group and 19/250 in the control group (4.4% vs 7.6%; p value = non significant). Supplementation with Sunactive Fe PPyrophosphate was associated with significantly higher ferritin level at the time of delivery, higher Hb level at the time of delivery and one month after delivery, and lower gastrointestinal side effects.

**Conclusion:** Our study provides newer evidence that demonstrates the effectiveness of Sunactive iron, with fewer side effects, in pregnant women with mild anemia. Larger randomized trials are required to confirm our data.

**Keywords:** Infertility, supplement

## Introduction

In pregnant women anemia is defined as hemoglobin (Hgb) level below 11 g/dL in the first trimester, or below 10.5 g/dL in the second trimester, or below 11 g/dL in the third trimester.<sup>[1]</sup> Anemia may be acquired, such as deficiency anemia (e.g. iron, vitamin B12, folate), hemorrhagic anemia, anemia of chronic disease, aplastic anemia, or inherited, such as thalassemia, sickle cell anemia, or hemoglobinopathies other than sickle cell anemia.

Iron deficiency anemia is extremely common during pregnancy. It is an acquired anemia characterized by increased red blood cell production with mean corpuscular volume (MCV) less than 80 fL (microcytic anemia).<sup>[1]</sup> A

national study of anemia in pregnancy found a prevalence of 22 per 1,000 pregnant women in the United States.<sup>[2]</sup>

Oral iron supplementation is the gold standard approach for iron deficiency anemia in pregnancy.<sup>[1]</sup> Different iron supplements are available on the market.<sup>[3]</sup> They include ferrous fumarate, ferrous sulfate, ferrous gluconate, iron dextran, ferric gluconate, and iron sucrose.<sup>[1,3]</sup> Micronized Ferric Pyrophosphate (SunActive®Fe) has been associated with better tolerability and effectiveness compared to oral ferrous sulfate in several studies.<sup>[4-6]</sup>

**Correspondence:** Gabriele Saccone, **e-mail:** gabriele.saccone.1990@gmail.com, **Received:** October 3, 2024 **Accepted:** February 14, 2025

**How to cite this article:** Napoli FD, Vigilante L, Trinchillo MG, Esposito G, Turco M, Gragnano E, Colacurci D, Saccone G. Effect of oral supplementation with micronized ferric pyrophosphate in pregnant women to prevent postpartum hemorrhage. Perinatal Journal 2025;33(1):25-27 DOI: 10.59215/prn.24.0323005

**ORCID ID:** FD Napoli 0009-0009-0236-4047; L Vigilante 0009-0000-6911-301X; MG Trinchillo 0009-0001-9311-0617; G Esposito 0000-0003-0078-7455; M Turco 0000-0003-0078-4771; E Gragnano 0000-0002-7963-2144; D Colacurci 0009-0000-8935-5710; G Saccone 0000-0003-0078-2113

## Objective

The aim of this study was to evaluate the impact of oral supplementation with micronized ferric pyrophosphate in pregnant women to prevent postpartum hemorrhage.

## Methods

This was an observational retrospective study using data from clinical records of women with anemia who had visits at our private setting center. Data were collected in a dedicated encrypted database and anonymized.

In this study, women who received oral supplementation with oral Micronized Ferric Pyrophosphate (SunActive Fe), coated with monoglycerides and diglycerides to minimize particle aggregation, plus Vitamin C, Folate, Copper and Vitamin B12 (Emefer) daily as prophylactic treatment for iron deficiency anemia were compared with women who did not. The intervention group received Emefer cpr (SunActive Fe 30 mg, Vitamin C 100 mg, Copper 1,50 mg, Folate 400 mcg, and Vitamin B12 2,75 mcg). The intervention group received the supplementation starting from the diagnosis of anemia until the day of delivery. The control group received standard care, i.e. ferrous sulphate (daily 80 mg Fe+2), starting from the diagnosis of anemia until the day of delivery.

Inclusion criteria were singleton gestations with microcytic mild iron deficiency anemia. Mild anemia was defined as Hgb level between 9.00 and 10.99 g/dL. Exclusion criteria were multiple gestations, and moderate or severe anemia defined as Hgb level below 9.00 g/dL.

The primary outcome of the study was the incidence of postpartum hemorrhage (PPH). The secondary outcomes were rise in serum ferritin, rise in Hgb level and maternal tolerability.

Statistical analysis was performed using Statistical Package for Social Sciences (SPSS) v. 19.0 (IBM Inc., Armonk, NY, USA). Data were shown as means± standard deviation or as number (percentage). Dichotomous data were compared using the chi-square. Comparisons between groups were performed with the use of the T-test to test group means by assuming equal within-group variances. A sample size of 500 women was planned.

## Results

500 women were included in the study. 250 received the intervention, and 250 were included in a control group matched for demographics. No significant differences were found in baseline characteristics, shown in Table 1. The mean BMI was 23.4 in the intervention group, and 21.8 in the control group. 4 women in the intervention

group had prior PPH in a prior pregnancy, and 7 in the control group.

Primary and secondary outcomes were shown in Table 2. PPH occurred in 11/250 women in the intervention group and 19/250 in the control group (4.4% vs 7.6%; p value = non significant). Supplementation with Micronized Ferric Pyrophosphate was associated with significantly higher ferritin level at the time of delivery, higher Hb level at the time of delivery and one month after delivery, and lower gastrointestinal side effects (Table 2).

**Table 1.** Maternal characteristics

	Intervention group N = 250	Control group N = 250	p-value
<b>BMI</b>	23.4±7.8	21.8±6.2	NS
<b>Smoking</b>	21 (8.4%)	29 (11.6%)	NS
<b>Prior PPH</b>	4 (1.6%)	7 (2.8%)	NS
<b>Nulliparous</b>	190 (76.0%)	178 (71.2%)	NS

NS, non significant; PPH, post partum hemorrhage

**Table 2.** Primary and secondary outcomes

	Intervention group N = 250	Control group N = 250	p-value
<b>PPH</b>	11 (4.4%)	19 (7.6%)	NS
<b>Ferritin level the day of delivery (micrograms per liter)</b>	19±3.2	8.4±4.6	<0.05
<b>Hb level the day of delivery (g/dl)</b>	11.4±2.3	10.2±2.5	<0.05
<b>Hb drop 24h after delivery (g/dl)</b>	1.8±0.9	1.7±1.1	NS
<b>Hb level one month after delivery (g/dl)</b>	13.4±4.2	11.8±3.5	<0.05
<b>Nausea</b>	20 (8%)	98 (39.2%)	<0.05
<b>Diarrhoea</b>	29 (11.6%)	69 (27.6%)	<0.05
<b>Black or tarry stools</b>	32 (12.8%)	103 (41.2%)	<0.05

NS, non significant; PPH, post partum hemorrhage; Hb, hemoglobin

## Discussion

This study found that the use of Micronized Ferric Pyrophosphate compared to standard ferrous sulphate, in pregnant women with mild anemia, is associated with increase hb level and trend for benefit in reduction of PPH.

Iron deficiency and iron anemia are highly prevalent and are the most common cause of anemia in pregnant women.<sup>[7-11]</sup> Both iron deficiency and iron deficiency anemia represent significant health problems in pregnant

women. Anemia may lead to prolonged length of stay in the hospital in the postpartum period, impaired quality of life, and depression. In addition it has other manifestations, including tiredness, and hair loss.

Gold standard treatment is oral iron supplementation, especially ferrous sulfate.<sup>[12]</sup> However, it is associated with gastrointestinal side effects.<sup>[13]</sup> Intravenous iron administration is more costly<sup>[14]</sup>, and may cause hypersensitivity reactions.<sup>[13]</sup>

Sunactive Fe is a micronized FePP coated with monoglycerides and diglycerides to minimize particle aggregation.<sup>[16-18]</sup> These properties result in higher absorption and gastrointestinal tolerance. The absorption of Micronized iron is indeed mostly hepcidin-independent, and preliminary data suggested efficacy in treatment iron deficiency anemia.<sup>[19]</sup>

## Conclusion

Our study provides newer evidence that demonstrates the effectiveness of SunActive Fe, with fewer side effects, in pregnant women with mild anemia. Larger randomized trial are required to confirm our data.

## References

1. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 95: anemia in pregnancy. *Obstet Gynecol.* 2008 Jul;112(1):201-7. [[PubMed](#)][[CrossRef](#)]
2. Adebisi OY, Strayhorn G. Anemia in pregnancy and race in the United States: blacks at risk. *Fam Med* 2005;37:655-62
3. Moe S, Grill AK, Allan GM. Newer iron supplements for anemia. *Can Fam Physician.* 2019 Aug;65(8):556.
4. Dede A, Uygur D, Yilmaz B, Mungan T, Uğur M. Intravenous iron sucrose complex vs. oral ferrous sulfate for postpartum iron deficiency anemia. *Int J Gynaecol Obstet.* 2005 Sep;90(3):238-9 [[PubMed](#)][[CrossRef](#)]
5. El Khoully NI. Comparison of intravenous ferrous sucrose and oral ferrous sulphate in treatment of postpartum iron deficiency anemia. *J Matern Fetal Neonatal Med.* 2017 Apr;30(8):967-971 [[PubMed](#)][[CrossRef](#)]
6. Briguglio M, Hrelia S, Malaguti M, De Vecchi E, Lombardi G, Banfi G, Riso P, Porrini M, Romagnoli S, Pino F, Crespi T, Perazzo P. Oral Supplementation with Micronized Ferric Pyrophosphate Plus L-Ascorbic Acid to Ameliorate the Maternal Status: A Randomized Controlled Trial. *Nutrients.* 2020 Jan 31;12(2):386 [[PubMed](#)][[CrossRef](#)]
7. Gómez-Ramírez S, Brilli E, Tarantino G, Girelli D, Muñoz M. Micronized® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency. *Pharmaceuticals (Basel).* 2023 Jun 6;16(6):847. [[PubMed](#)][[CrossRef](#)]
8. Pantopoulos K. Oral iron supplementation: new formulations, old questions. *Haematologica.* 2024 Sep 1;109(9):2790-2801. [[PubMed](#)][[CrossRef](#)]
9. Gómez-Ramírez S, Brilli E, Tarantino G, Muñoz M. Micronized® Iron: A New Generation Iron for Improving Oral Supplementation. *Pharmaceuticals (Basel).* 2018 Oct 4;11(4):97. [[PubMed](#)][[CrossRef](#)]
10. Karami M, Chalesghar M, Salari N, Akbari H, Mohammadi M. Global Prevalence of Anemia in Pregnant Women: A Comprehensive Systematic Review and Meta-Analysis. *Matern Child Health J.* 2022 Jul;26(7):1473-1487. [[PubMed](#)][[CrossRef](#)]
11. Gallo A, D'Alisa R, Foreste V, Saccone G, De Angelis MC, Di Spiezio Sardo A, Zizolfi B. Cavernous haemangioma and mid trimester pregnancy loss leading to severe haemorrhage and hysterectomy: a case report and review of literature. *Facts Views Vis Obgyn.* 2023 Dec;15(4):339-349. [[PubMed](#)][[CrossRef](#)]
12. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. *Am J Hematol.* 2016 Jan;91(1):31-8. [[PubMed](#)][[CrossRef](#)]
13. Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. *PLoS One.* 2015 Feb 20;10(2):e0117383. [[PubMed](#)][[CrossRef](#)]
14. Ray S, Neogi SB, Singh R, Devasenapathy N, Zodpey S. Is IV iron sucrose a cost-effective option for treatment of severe anaemia in pregnancy as compared with oral iron? *Health Policy Plan.* 2021 Feb 16;35(10):1339-1346. [[PubMed](#)][[CrossRef](#)]
15. Rampton D, Folkersen J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, Patni S, Szebeni J, Weiss G. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. *Haematologica.* 2014 Nov;99(11):1671-6. [[PubMed](#)][[CrossRef](#)]
16. Bastida G, Herrera-de Guise C, Algaba A, Ber Nieto Y, Soares JM, Robles V, Bermejo F, Sáez-González E, Gomollón F, Nos P. Micronized Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment. *Nutrients.* 2021 May 22;13(6):1770. [[PubMed](#)][[CrossRef](#)]
17. Roe MA, Collings R, Hoogewerff J, Fairweather-Tait SJ. Relative bioavailability of micronized, dispersible ferric pyrophosphate added to an apple juice drink. *Eur J Nutr.* 2009 Mar;48(2):115-9. [[PubMed](#)][[CrossRef](#)]
18. Kim HJ, Bae SH, Kim HJ, Kim KM, Song JH, Go MR, Yu J, Oh JM, Choi SJ. Cytotoxicity, Intestinal Transport, and Bioavailability of Dispersible Iron and Zinc Supplements. *Front Microbiol.* 2017 Apr 28;8:749. [[PubMed](#)][[CrossRef](#)]
19. Berardi S, Foltran L, Pascoli I, Pepe A, Salmeri M.G, Busato E. Efficacy of oral Micronized® iron in puerperium anemia. *Exp. Rev. Hematol.* 2016;9(Suppl. S1):40

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported (CC BY-NC-ND4.0) License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.